Pharmaceutical companies are adopting shrewd strategies to effectively compete in the tauopathies space, observes a report by GlobalData.

Titled ‘PharmaFocus: Tauopathies–Global Market Analysis’, the report details the strategies employed by pharmaceutical companies in the tauopathies market, which is yet to see the launch of a first drug.

Some of these strategies include licensing agreements and co-development partnerships. The discovery stage of potential tauopathy therapies is usually carried out by small biotechnology companies. The later stages of development are then carried out by large pharma companies.

Anavir / Otsuka’s AVP-796, Sellas Life Sciences Group / Catalent’s zolpidem, AbbVie / C2N Diagnostics’ ABBV-8E12, and Merck & Co. / Alectos Therapeutics’ MK-8719 are some examples of such partnerships.

"Pharmaceutical companies are specifically focusing on developing tauopathies and Alzheimer’s disease therapies in parallel, says Akiko Fukui, MSc, Healthcare Analyst for GlobalData."

Companies are also developing products simultaneously for multiple indications, in order to reduce research efforts and costs. AbbVie / C2N Diagnostics’ ABBV-8E12, TauRX Therapeutics’ TRx-237 and Cortice Biosciences’ TPI-287 are some examples of drugs being developed for multiple indications.

Pharmaceutical companies are specifically focusing on developing tauopathies and Alzheimer’s disease therapies in parallel, says Akiko Fukui, MSc, Healthcare Analyst for GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tauopathies and Alzheimer’s disease have common disease pathways. Research carried out on Alzheimer’s can, therefore, be applied to the development of tauopathies drugs and vice versa.

Pursuing multiple indications further helps pharma companies to build a strong portfolio of drugs, thereby reducing risk and increasing the chances of delivering clinical drug candidates. Neurimmune Holding, for example, is currently evaluating three pipeline products, BIIB076, NI205, and NI-308, which are in preclinical stages of development, explains Akiko Fukui.